T10B9 (MEDI-500) mediated immunosuppression: Studies on the mechanism of action

Clinical Transplantation

Volumn 10, Issue 6 II, 1996, Pages 607-613

  Brown, Stephen A ^a   Lucas, Bruce A ^b   Waid, Thomas H ^b   McKeown, J Wade ^b   Barve, Shirish ^b   Jackson, Lisa R ^b   Thompson, John S ^b  

^a LEXINGTON VA MEDICAL CENTER   (United States)

^b NONE

Author keywords

Antibody; Cytokines; Kidney; Monoclonal; Transplantation

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 2; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY T10B9; OKT 3; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; DRUG MECHANISM; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT REJECTION; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; APOPTOSIS; CYTOKINES; DRUG EVALUATION, PRECLINICAL; GRAFT REJECTION; HUMANS; IMMUNOGLOBULIN M; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LYMPHOCYTE ACTIVATION; MUROMONAB-CD3; RECEPTOR-CD3 COMPLEX, ANTIGEN, T-CELL; SIGNAL TRANSDUCTION;

EID: 0030478630     PISSN: 09020063     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. WALDMANN TA. Monoclonal antibodies in diagnosis and therapy. Science 1991: 252: 1657.
2. KAHAN BD ed. Monoclonal antibodies: Today and tomorrow. Transp Immunol Lett 1991: 7 (no.2): 1.
3. BORREBAECK CAK, LARRICK JW, eds. Therapeutic Monoclonal antibodies. Stockton, New York: 1990.
4. WALDMANN TA, ed. Monoclonal antibody therapy. In: Ishizaka K, Kallos P, Lachmann PJ, Waksman BH eds. Progress in Allergy, Vol 45. Basel: Karger, 1988.
5. CHATENOUD L. Monoclonal antibodies. Curr Opin Immunol 1989: 2: 246.
6. ORTHO MULTICENTER TRANSPLANT STUDY GROUP. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. N Engl J Med 1985: 313: 337.
7. COSIMI AB, BURTON RC, COLVIN B et al. Treatment of acute renal allograft rejection with OKT3 monoclonal antibody. Transplantation 1981: 32: 535.
8. ABRAMOWICZ D, SEHANDENE L, GOLDMAN M. Release of tumor necrosis factor, interleukin-2, and gamma-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients. Transplantation 1989: 47: 606.
9. CHATENOUD L, FERRAN C, REUTER A et al. Systemic reaction to the anti-T cell monoclonal antibody OKT3 in relation to serum levels of tumor necrosis factor and interferon-gamma. N Engl J Med 1989: 320: 1420.
10. TAX WJ, WILLEMS HW, REEKERS PP, CAPEL PJ, KOENE RA. Polymorphism in mitogenic effect of IgG1 monoclonal antibodies against T3 antigen on human T cells. Nature, (London) 1983: 304: 445.
11. SMITH KGC, AUSTYN JM, HARIRI G, BEVERLY PCL, MORRIS PJ. T cell activation by anti-T3 antibodies: Comparison of IgG1 and IgG2b switch varients and direct evidence for accessory functions of macrophage Fc receptors. Eur J Immunol 1986: 16: 478.
12. CEUPENS JL, BLOEMMEN FJ, VAN WAUWE JP T cell unresponsiveness to the mitogenic activity of OKT3 antibody results from a deficiency of monocyte Fc-alpha receptors for murine IgG2a and inability to cross-link the T3-Ti complex. J Immunol 1985: 135: 3882.
13. WAID TH, LUCAS BA, THOMPSON JS et al. Treatment of acute cellular kidney allograft rejection with T10B9. 1A-31 anti-T-cell monoclonal antibody. Transpl Proc 1989: 21: 1778.
14. WAID TH, LUCAS BA, AMLOT P et al. T10B9. 1A-31 anti-T-cell monoclonal antibody: preclinical studies and clinical treatment of solid organ allograft rejection. Am J Kid Dis 1989: 14. s2: 61.
15. WAID TH, LUCAS BA, THOMPSON JS et al. Treatment of acute rejection with anti-T-cell antigen receptor complex α/ β (T10B9.1A-31) or anti-CD3 (OKT3) monoclonal antibody: results of a prospective randomized double-blind trial. Transpl Proc 1991: 23: 1062.
16. WAID TH, LUCAS BA, THOMPSON JS et al. Treatment of acute cellular rejection with T10B9. 1A-31 or OKT3 in renal allograft recipients. Transplantation 1992: 53: 80.
17. DEBETS JMH, LEUNISSEN KML, VAN HOOFF HJ, VAN DER LINDEN CJ, BUURMAN WA. Evidence of involvement of tumor necrosis factor in adverse reaction during treatment of kidney allograft rejection with antithymocyte globulin. Transplantation 1989: 47: 487.
18. COMPTON MM, CIDLOWSKI JA. Rapid in vivo effects of glucocorticoids on the integrity of rat lymphocyte genomic deoxyribonucleic acid. Endocrinology 1986: 118: 38
19. CHIU L, CHERWINSKI H, RANSOM J, DUNNE JE Ratiometric hoecchst 33342 emission analysis allows multiparametric characterization of apoptotic lymphocytes. J Immunol Meth 1995: 189: 157.
20. VAN WAUWE J, DEMEY J, GOOSSENS J. OKT3: A monoclonal anti-human T lymphocyte antibody with potent mitogenic properties. J Immunol 1980: 124: 2708.
21. ELLENHORN JDL WOODLE ES, GHOBREAL I, THISTLETHWAITE, BLUESTONE JA. Activation of human T cells in vivo following treatment of transplant recipients with OKT3. Transplantation 1990: 50: 608.
22. FERRAN C, SHEEHAN K, SEHREIBER R, BACH JF, CHATENOUD L. Anti-TNF abrogates the cytokine-related anti-CD3 induced syndrome. Transpl Proc 1991: 23: 849.
23. JANSSEN O, WESSELBORG S, KABELITZ D. Immunosuppression by OKT3-Induction of programmed cell death (apoptosis) as a possible mechanism of action. Transplantation 1991: 53: 233.
24. CHANG TW, GINGRAS SP. OKT3 monoclonal antibody inhibits cytotoxic T lymphocyte mediated cell lysis. Int J Immunopharm 1981: 3: 183.
25. FRENKEN LAM, KOENE RAP, TAX WJM. The role of antibody isotype in IFN-γ and IL-2 production during anti-CD3-induced T cell proliferation. Transplantation 1991: 51: 881.
26. RAO PE, OLINI G, KILLE J et al. OKT3E, an anti-CD3 antibody that does not elicit side effects or antiidiotype responses in chimpanzees. Transplantation 1991: 52: 691.
27. PARLEVLIET KJ, JONKER M, TEN BERGE RJM et al. Anti-CD3 murine monoclonal isotype switch variants tested for toxicity and immunologic monitoring in four chimpanzees. Transplantation 1990: 50: 889.
28. WOODLE ES, THISTLEWAITE JR, GHOBREAL IA, JOLLIFFE LK, STUART FP, BLUESTONE JA. OKT3 F(ab′)2 fragments - retention of the immunosuppressive properties of whole antibody with marked reduction in T cell activation and lymphokine release. Transplantation 1991: 52: 354.
29. PALACIOS R. Mechanisms by which accessory cells contribute in growth of resting T lymphocytes initiated by OKT3 antibody. Eur J Immunol 1985: 15: 645.
30. O'FLYNN K, BEVERLEY PCL, LINCH DC. The influence of anti-T cell monoclonal antibodies on calcium mobilization: investigation of workshop antibodies. In: REINHERTZ EL, HAYNES BF, NADLER LM, BERNSTEIN ID, Eds. Leukocyte Typing II, Vol 1. New York: Springer-Verlag, 1986, p. 205.